Ongoing research is focused on developing more selective kinase inhibitors and combination therapies to overcome resistance. Advances in precision medicine and genomic profiling are helping to identify patient populations that are most likely to benefit from specific kinase inhibitors. Furthermore, novel approaches such as proteolysis-targeting chimeras (PROTACs) are being explored to degrade rather than inhibit oncogenic kinases.
